Aprea Therapeutics: A Focus on New Targets and Biomarkers in Oncology

Published on : Published by : Mark Terry

Ahead of presentations at the 6th Annual DDR Inhibitors Summit in Boston this week, Oren Gilad, Ph.D., president and CEO of Aprea, and Eric Brown, Ph.D., Scientific Consultant to Aprea, member of the company’s Scientific Advisory Board, and Associate Professor of Cancer Biology at the University of Pennsylvania, took time out to speak with BioBuzz about the company and the significance of new target and biomarker identification in oncology research.

A $365 Million Development Will Expand the Life Sciences Hub at Pennovation Works

Published on : Published by : BioBuzz Media

ennovation Works, the 23-acre University of Pennsylvania property just across the Schuylkill River from the core campus, has long been a site for innovation. Home to a ferry business in the 18th century, a paint company in the 19th century, and a DuPont chemical research facility for much of the 20th century, the space underwent a further transformation in 2016 with the establishment of the Pennovation Center, an incubator for science and technology startups, many of which have their origins within the University. Last year, the 65,000 square foot Pennovation Lab opened, offering larger lab spaces for companies outgrowing their previous locations.

Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies

Published on : Published by : BioBuzz Media

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the launch of its new Case Management Service, which has been specifically designed to address the unique challenges associated with the safe and timely delivery of advanced therapies to patients by providing professional supply chain oversight from program start to finish.

CBM Streamlines Cell and Gene Therapy Manufacturing Capabilities with Autolomous Digital Platform

Published on : Published by : Alex Keown

In its quest to be one of the top Contract Development and Manufacturing Organizations in the world, the Center for Breakthrough Medicines (CBM) will implement a robust digital solutions system that will support end-to-end cell and gene therapy manufacturing processes.

Passage Bio’s William Chou: Gene Therapy and Impactful Results for Patients

Published on : Published by : Mark Terry

The first gene therapy to be approved by the FDA occurred in late 2017. It was Spark Therapeutics’ Luxturna, approved for a rare, genetic form of blindness. Since then, a handful of additional gene therapies have been approved, including bluebird bio’s Zynteglo for beta-thalassemia, which is expected to launch in March 2023. The Alliance for Regenerative Medicine predicts five more gene therapies may be approved this year.

Athletes and Scientists Partner to Support Rare Disease Research

Published on : Published by : Alex Keown

Sponsored by the not-for-profit Uplifting Athletes, the Young Investigators Draft provides $20,000 grants to 10 beginning-career stage research scientists in the rare disease community. The award is an unrestricted grant that will support the vital investigation of potential therapies and cures, including gene therapies, for rare disease, said Rob Long, executive director of Uplifting Athletes.

Agenda 2023: PQE Group Boosting Growth by Reinforcing Service Portfolio and Entering New Markets

Published on : Published by : BioBuzz Media

It has been another successful year for PQE Group, a consulting firm in the Life Sciences industry based in Florence (Italy) with 32 offices worldwide. Recently named “Best Managed Company” by Deloitte, the Group closed in 2022 with a +70% in revenues compared to the previous year, thanks to the tremendous growth in the US and other international markets.

Leap Therapeutics Buys Pennsylvania-based Flame Biosciences for Access to Anti-Claudin18.2 Antibody

Published on : Published by : Mark Terry

Leap Therapeutics, headquartered in Cambridge, Mass., acquired New Hope, Pa.-based Flame Biosciences. The primary focus of the merger was for Leap to pick up Flame’s FL-301, a clinical-stage anti-Claudin18.2 monoclonal antibody.